Bonsai Biotherapeutics is a biopharmaceutical company developing disease-modifying therapies for autoimmune diseases. Its platform is based on tolerogens – biological drugs designed to restore immune tolerance to specific autoantigens. By targeting the disease process at its source, unlike current therapies that suppress or reduce immune function broadly, Bonsai aims to provide long-lasting therapeutic benefit while preserving normal immune system capacity. Bonsai’s lead asset, TOL2, is a protein tolerogen for AChR antibody-positive generalized myasthenia gravis, a serious orphan indication with substantial unmet need. With its focus on restoring immune balance, the company seeks to transform the treatment of autoimmune diseases and improve the lives of patients.
